← Back to Clinical Trials
Recruiting NCT06870006

NCT06870006 Psychotropic-Drug-induced QT Prolongation and ECG Monitoring in the Pediatric Population

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06870006
Status Recruiting
Phase
Sponsor Meyer Children's Hospital IRCCS
Condition Eating Disorders
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2024-01-01
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 18 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2024-01-01 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Electrocardiogram (ECG) Q-T prolongation is a cardiac electrophysiological disorder associated with the occurrence of arrhythmias potentially fatal. Several psychotropic drugs are associated with an increased risk of QT prolongation, which is why in clinical practice a baseline ECG is performed before a psychotropic drug is prescribed. However, there are no validated protocols establishing when to repeat this examination or describing clinical events when this examination should be repeated in clinical follow-up. The study aims to investigate the incidence of QTc prolongation events as a side effect of chronic psychotropic drug administration. For this purpose, ECGs will be recorded and confounding factors of patients at the beginning of psychotropic therapy and after 3, 6 and 12 months will be analyzed.

Eligibility Criteria

Inclusion Criteria: * Admitted to psychiatry ward * Starting a psychotropic drug acting on QT interval Exclusion Criteria: * Age \>18aa * History of administration of drug acting on QT interval in the 3 months prior

Contact & Investigator

Central Contact

Tiziana Pisano, MD

✉ tiziana.pisano@meyer.it

📞 3498705830

Frequently Asked Questions

Who can join the NCT06870006 clinical trial?

This trial is open to participants of all sexes, up to 18 Years, studying Eating Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06870006 currently recruiting?

Yes, NCT06870006 is actively recruiting participants. Contact the research team at tiziana.pisano@meyer.it for enrollment information.

Where is the NCT06870006 trial being conducted?

This trial is being conducted at Troina, Italy, Florence, Italy, Calambrone, Italy, Bologna, Italy and 2 additional locations.

Who is sponsoring the NCT06870006 clinical trial?

NCT06870006 is sponsored by Meyer Children's Hospital IRCCS. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology